A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
02 2022
Historique:
received: 26 06 2021
accepted: 11 01 2022
revised: 23 02 2022
pubmed: 11 2 2022
medline: 4 3 2022
entrez: 10 2 2022
Statut: epublish

Résumé

Efforts to define serological correlates of protection against COVID-19 have been hampered by the lack of a simple, scalable, standardised assay for SARS-CoV-2 infection and antibody neutralisation. Plaque assays remain the gold standard, but are impractical for high-throughput screening. In this study, we show that expression of viral proteases may be used to quantitate infected cells. Our assays exploit the cleavage of specific oligopeptide linkers, leading to the activation of cell-based optical biosensors. First, we characterise these biosensors using recombinant SARS-CoV-2 proteases. Next, we confirm their ability to detect viral protease expression during replication of authentic virus. Finally, we generate reporter cells stably expressing an optimised luciferase-based biosensor, enabling viral infection to be measured within 24 h in a 96- or 384-well plate format, including variants of concern. We have therefore developed a luminescent SARS-CoV-2 reporter cell line, and demonstrated its utility for the relative quantitation of infectious virus and titration of neutralising antibodies.

Identifiants

pubmed: 35143592
doi: 10.1371/journal.ppat.1010265
pii: PPATHOGENS-D-21-01328
pmc: PMC8865646
doi:

Substances chimiques

Viral Proteins 0
Peptide Hydrolases EC 3.4.-

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010265

Subventions

Organisme : Medical Research Council
ID : MR/P008801/1
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

FASEB J. 2021 Jan;35(1):e21197
pubmed: 33368679
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Nat Commun. 2020 Nov 3;11(1):5559
pubmed: 33144569
bioRxiv. 2021 Feb 04;:
pubmed: 33501437
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Viruses. 2021 Jan 24;13(2):
pubmed: 33498923
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Front Cardiovasc Med. 2021 Jan 15;7:618651
pubmed: 33521067
Viruses. 2020 Oct 14;12(10):
pubmed: 33066701
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Virology. 2021 Apr;556:73-78
pubmed: 33548599
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell Res. 2020 Aug;30(8):678-692
pubmed: 32541865
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3338-43
pubmed: 25733847
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Elife. 2017 Mar 15;6:
pubmed: 28296633
Antimicrob Agents Chemother. 2009 Feb;53(2):728-34
pubmed: 19064890
J Am Chem Soc. 2019 Mar 20;141(11):4526-4530
pubmed: 30821975
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Trends Genet. 2000 Jun;16(6):276-7
pubmed: 10827456
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Antimicrob Agents Chemother. 2001 Sep;45(9):2616-22
pubmed: 11502538
J Virol. 2021 Jan 28;95(4):
pubmed: 33257477
EMBO Mol Med. 2021 Jan 11;13(1):e13105
pubmed: 33015938
J Infect Dis. 2020 Oct 1;222(9):1462-1467
pubmed: 32798217
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Mol Cell. 2016 May 19;62(4):572-85
pubmed: 27203180
Science. 2021 Mar 12;371(6534):1103-1104
pubmed: 33707254
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
J Virol. 2020 Oct 27;94(22):
pubmed: 32843534
Nucleic Acids Res. 1990 Oct 25;18(20):6097-100
pubmed: 2172928
PLoS One. 2010 Oct 06;5(10):e13197
pubmed: 20949131
J Virol. 2013 Nov;87(21):11955-62
pubmed: 23986593
PLoS Biol. 2021 Feb 25;19(2):e3001091
pubmed: 33630831
G3 (Bethesda). 2020 Sep 2;10(9):3399-3402
pubmed: 32763951
J Biol Chem. 2020 Feb 21;295(8):2212-2226
pubmed: 31919100
Science. 2015 Jun 26;348(6242):1481-1485
pubmed: 26022416
Curr Chem Genomics. 2008 Oct 17;2:16-28
pubmed: 20161840
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Elife. 2018 Dec 13;7:
pubmed: 30543180
Nat Commun. 2020 Aug 27;11(1):4282
pubmed: 32855413

Auteurs

Pehuén Pereyra Gerber (PP)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Lidia M Duncan (LM)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Edward Jd Greenwood (EJ)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Sara Marelli (S)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Adi Naamati (A)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Ana Teixeira-Silva (A)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Thomas Wm Crozier (TW)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Ildar Gabaev (I)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Jun R Zhan (JR)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.

Thomas E Mulroney (TE)

MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.

Emily C Horner (EC)

MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.

Rainer Doffinger (R)

Department of Clinical Biochemistry and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Anne E Willis (AE)

MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.

James Ed Thaventhiran (JE)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.

Anna V Protasio (AV)

Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

Nicholas J Matheson (NJ)

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.
NHS Blood and Transplant, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH